NextCure announces acceptance of IND application for LNCB74

NextCure (NXTC) announced that the U.S. Food and Drug Administration, FDA, accepted an Investigational New Drug, IND, application for initiation of a Phase 1 clinical trial to evaluate LNCB74, a B7-H4-targeting antibody-drug conjugate, ADC, as a therapeutic for treating multiple cancers. “Acceptance of the IND application for LNCB74 represents an important milestone for NextCure as we focus our resources on advancing our ADC program,” said Michael Richman, NextCure’s president and CEO. “The IND application leverages LNCB74 preclinical data that highlights the differentiation of our B7-H4 ADC from other ADCs targeting B7-H4. We believe LNCB74 has the potential to transform treatment for patients and we look forward to advancing LNCB74 into clinical development.”